

16 December 2024

Issue of Securities Following AGM Approval, Placement to Satisfy Prior Invoice

HITIQ Limited (ASX: HIQ) (HITIQ or the Company) advises that, pursuant to shareholder approval at its 2024 Annual General Meeting (**AGM**) held 27 November 2024, it will proceed with Issuing the following securities, effective 16 December 2024:

- 656,250 HIQ ordinary shares each to directors Phil Carulli, Matt Clayworth and James Barrie in satisfaction of 50% of their accrued director fees; and
- 2,500,000 HIQ ordinary shares to director Earl Eddings in satisfaction of consultancy fees prior to his appointment.

In addition, the Company has agreed to partially settle an invoice relating to its non-renounceable rights issue announced 16 October 2023, by way of issuance of 3,000,690 HIQ ordinary shares. This issue will be conducted under the Company's 7.1 placement capacity.

The following unlisted Incentive award Shares and Performance Rights for Earl Eddings (also approved by shareholders at the AGM) were also issued effective 16 December 2024:

- 1,750,000 unlisted ordinary shares; and
- 5,250,000 unlisted Performance Rights.

An Appendix 3B, Appendix 3G's and associated Appendix 3Y's will be lodged separately on ASX to reflect the new securities being issued.

This announcement is authorised for release by the HITIQ Board of Directors.

Ends -

For more information:

Shareholders: investors@hitiq.com

Media: Andrew Crook 0419 788 431



About HITIQ

HITIQ has an evidenced-based brain care solution company deploying world-class technologies.

Our solutions include a sensor-enabled mouthguard to an AI-enabled data analytics interface and, best in class return to play/work support software.

Our technology enables data driven decisions for thousands of professional and amateur sports players who experience brain impacts, empowers clinicians who care for their brains and enhance concussion management policies for progressive leagues around the globe.

Our customers include the Australian Football League (AFL), English Premier League (EPL), and the National Rugby League (NRL), along with numerous other teams in a variety of sporting codes. We also service universities and research organisations studying the impacts (both short and long-term) of repeat head impacts.